Literature DB >> 10529091

Apolipoprotein B mRNA editing and apolipoprotein gene expression in the liver of hyperinsulinemic fatty Zucker rats: relationship to very low density lipoprotein composition.

M B Elam1, M A von Wronski, L Cagen, F Thorngate, P Kumar, M Heimberg, H G Wilcox.   

Abstract

We previously demonstrated increased apolipoprotein B (apoB) mRNA editing, elevated levels of mRNA for the catalytic component of the apoB mRNA editing complex, apobec-1, and increased secretion of the product of the edited mRNA, apoB48, in very low density lipoproteins (VLDL) in primary cultures of Sprague-Dawley rat hepatocytes following insulin treatment. In order to determine the effect of in vivo hyperinsulinemia on these processes, we determined apoB mRNA editing, apobec-1 expression, hepatic expression of mRNA for apoB and other VLDL apoproteins, and the quantity and composition of plasma VLDL in the hyperinsulinemic fatty Zucker rat. Total apoB mRNA content of the livers of the fatty rats and lean littermates did not differ; however, edited apoB message coding for hepatic apo B48, and abundance of mRNA for the catalytic subunit of the apoB mRNA editing complex, apobec-1, was increased by 1.7- and 3.3-fold, respectively, in fatty rats. ApoCIII mRNA abundance was increased in livers of fatty rats as well, but the abundance of hepatic apoE mRNA in the fatty animal was not different from that of the lean rat. Hepatic apoAI mRNA abundance was also increased in the fatty rats. Associated with increased apoB mRNA editing, was the 1.7-fold increase in the fraction of apoB in plasma as apoB48 in fatty rats. VLDL-triglyceride and -apoB in plasma were 15- and 3-fold higher, respectively, in fatty Zucker rats compared to lean littermates, indicating both enrichment of VLDL with triglycerides and increased accumulation of VLDL particles. Increased hepatic expression of mRNA for apoCIII and apoAI was associated with increased content of apoC (and relative depletion of apoE) in VLDL of fatty rats, and plasma apoAI was increased in fatty Zucker rats, primarily in the HDL fraction. The current study provides further evidence that chronic exposure to high levels of insulin influences both the quantity of and lipid/apoprotein composition of VLDL in plasma. The increased apoC and decreased apoE (as well as increased triglyceride) content of VLDL in the fatty Zucker rat observed in the current study may affect VLDL clearance and therefore may be a factor in the observed accumulation of VLDL in the plasma of the fatty hyperinsulinemic Zucker rats.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529091     DOI: 10.1007/s11745-999-0427-z

Source DB:  PubMed          Journal:  Lipids        ISSN: 0024-4201            Impact factor:   1.880


  41 in total

1.  Lipoproteins in the plasma and hepatic perfusates of the Zucker fatty rat.

Authors:  J L Witztum; G Schonfeld
Journal:  Diabetes       Date:  1979-05       Impact factor: 9.461

2.  Catabolism of chylomicron triacylglycerol and cholesteryl ester in genetically obese rats.

Authors:  T G Redgrave
Journal:  J Lipid Res       Date:  1977-09       Impact factor: 5.922

3.  A modification of the Lowry procedure to simplify protein determination in membrane and lipoprotein samples.

Authors:  M A Markwell; S M Haas; L L Bieber; N E Tolbert
Journal:  Anal Biochem       Date:  1978-06-15       Impact factor: 3.365

4.  Evidence for a common, saturable, triglyceride removal mechanism for chylomicrons and very low density lipoproteins in man.

Authors:  J D Brunzell; W R Hazzard; D Porte; E L Bierman
Journal:  J Clin Invest       Date:  1973-07       Impact factor: 14.808

5.  Obese Zucker (fa/fa) rats are resistant to insulin's inhibitory effect on hepatic apo B secretion.

Authors:  J D Sparks; C E Sparks
Journal:  Biochem Biophys Res Commun       Date:  1994-11-30       Impact factor: 3.575

6.  The effect of fasting on the secretion of lipoproteins and two forms of apo B by perfused rat liver.

Authors:  J B Marsh; C E Sparks
Journal:  Proc Soc Exp Biol Med       Date:  1982-06

7.  Fasting decreases apolipoprotein B mRNA editing and the secretion of small molecular weight apoB by rat hepatocytes: evidence that the total amount of apoB secreted is regulated post-transcriptionally.

Authors:  J K Leighton; J Joyner; J Zamarripa; M Deines; R A Davis
Journal:  J Lipid Res       Date:  1990-09       Impact factor: 5.922

8.  Uptake of chylomicrons by the liver, but not by the bone marrow, is modulated by lipoprotein lipase activity.

Authors:  M M Hussain; I J Goldberg; K H Weisgraber; R W Mahley; T L Innerarity
Journal:  Arterioscler Thromb Vasc Biol       Date:  1997-07       Impact factor: 8.311

9.  Hepatocyte polyploidy and metabolism/life-history traits: hypotheses testing.

Authors:  O V Anatskaya; A E Vinogradov; B N Kudryavtsev
Journal:  J Theor Biol       Date:  1994-05-21       Impact factor: 2.691

10.  Transcriptional regulation of the apoC-III gene by insulin in diabetic mice: correlation with changes in plasma triglyceride levels.

Authors:  M Chen; J L Breslow; W Li; T Leff
Journal:  J Lipid Res       Date:  1994-11       Impact factor: 5.922

View more
  4 in total

1.  Mouse and other rodent models of C to U RNA editing.

Authors:  Valerie Blanc; Nicholas O Davidson
Journal:  Methods Mol Biol       Date:  2011

2.  Dual action of neutral sphingomyelinase on rat hepatocytes: activation of cholesteryl ester metabolism and biliary cholesterol secretion and inhibition of VLDL secretion.

Authors:  Mariana Liza; Yolanda Chico; Olatz Fresnedo; Begoña Ochoa
Journal:  Lipids       Date:  2003-01       Impact factor: 1.880

3.  Hepatic and adipose tissue depot-specific changes in lipid metabolism in Late-onset Obese (LOB) rats.

Authors:  Fredrik Frick; Randip Hume; Iain C Robinson; Staffan Edén; Jan Oscarsson
Journal:  Lipids       Date:  2008-03-12       Impact factor: 1.880

4.  Exploring the potential of the platelet membrane proteome as a source of peripheral biomarkers for Alzheimer's disease.

Authors:  Laura E Donovan; Eric B Dammer; Duc M Duong; John J Hanfelt; Allan I Levey; Nicholas T Seyfried; James J Lah
Journal:  Alzheimers Res Ther       Date:  2013-06-13       Impact factor: 6.982

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.